Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts

Molecular Oncology

Volumn 7, Issue 1, 2013, Pages 130-142

  Borgan, Eldrid ^a,b,c   Lindholm, Evita M ^a   Moestue, Siver ^c   Mælandsmo, Gunhild M ^a,d   Lingjærde, Ole Christian ^e   Gribbestad, Ingrid S ^c   Børresen Dale, Anne Lise ^a,b   Engebraaten, Olav ^a,f   Sørlie, Therese ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d UNIVERSITY OF TROMSØ   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Bevacizumab; Breast cancer; Metabolomics; Transcriptomics; Xenograft

Indexed keywords

BEVACIZUMAB; DOXORUBICIN; HEMOGLOBIN CHAIN; HEMOGLOBIN THETA 1; TRANSCRIPTOME; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CONTROLLED STUDY; DNA REPLICATION; DRUG RESPONSE; GENE EXPRESSION; HUMAN; HUMAN CELL; METABOLOME; PHENOTYPE; PHOSPHOLIPID METABOLISM; PREDICTIVE VALUE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR XENOGRAFT;

MUS;

EID: 84872500139     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.10.005     Document Type: Article

References (48)

1. Baar J., Silverman P., Lyons J., Fu P., Abdul-Karim F., Ziats N., Wasman J., Hartman P., Jesberger J., Dumadag L., Hohler E., Leeming R., Shenk R., Chen H., McCrae K., Dowlati A., Remick S.C., Overmoyer B. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clinical Cancer Research 2009, 15:3583-3590.
2. Barzilai A., Horowitz A., Geier A., Degani H. Phosphate metabolites and steroid hormone receptors of benign and malignant breast tumors. A Nuclear Magnetic Resonance study. Cancer 1991, 67:2919-2925.
3. Bear H.D., Tang G., Rastogi P., Geyer C.E., Robidoux A., Atkins J.N., Baez-Diaz L., Brufsky A.M., Mehta R.S., Fehrenbacher L., Young J.A., Senecal F.M., Gaur R., Margolese R.G., Adams P.T., Gross H.M., Costantino J.P., Swain S.M., Mamounas E.P., Wolmark N. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. The New England Journal of Medicine 2012, 366:310-320.
4. Beloueche-Babari M., Chung Y.L., Al-Saffar N.M., Falck-Miniotis M., Leach M.O. Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy. The British Journal of Cancer 2010, 102:1-7.
5. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B (Methodological) 1995, 57:289-300.
6. Bergamaschi A., Hjortland G.O., Triulzi T., Sørlie T., Johnsen H., Ree A.H., Russnes H.G., Tronnes S., Maelandsmo G.M., Fodstad O., Borresen-Dale A.L., Engebraaten O. Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Molecular Oncology 2009, 3:469-482.
7. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer 2008, 8:592-603.
8. Braghiroli M.I., Sabbaga J., Hoff P.M. Bevacizumab: overview of the literature. Expert Review of Anticancer Therapy 2012, 12:567-580.
9. Burstein H.J. Bevacizumab for advanced breast cancer: all tied up with a RIBBON?. Journal of Clinical Oncology 2011, 29:1232-1235.
10. Caiazza F., McCarthy N.S., Young L., Hill A.D., Harvey B.J., Thomas W. Cytosolic phospholipase A2-alpha expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours. British Journal of Cancer 2011, 104:338-344.
11. Chi J.T., Wang Z., Nuyten D.S., Rodriguez E.H., Schaner M.E., Salim A., Wang Y., Kristensen G.B., Helland A., Borresen-Dale A.L., Giaccia A., Longaker M.T., Hastie T., Yang G.P., van de Vijver M.J., Brown P.O. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Medicine 2006, 3:e47.
12. Du R., Lu K.V., Petritsch C., Liu P., Ganss R., Passegue E., Song H., Vandenberg S., Johnson R.S., Werb Z., Bergers G. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13:206-220.
13. Durinck S., Moreau Y., Kasprzyk A., Davis S., De Moor B., Brazma A., Huber W. BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. Bioinformatics 2005, 21:3439-3440.
14. Eden E., Navon R., Steinfeld I., Lipson D., Yakhini Z. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 2009, 10:48.
15. Eliyahu G., Kreizman T., Degani H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. International Journal of Cancer 2007, 120:1721-1730.
16. Enerly E., Steinfeld I., Kleivi K., Leivonen S.K., Aure M.R., Russnes H.G., Ronneberg J.A., Johnsen H., Navon R., Rodland E., Makela R., Naume B., Perala M., Kallioniemi O., Kristensen V.N., Yakhini Z., Borresen-Dale A.L. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One 2011, 6:e16915.
17. Gentleman R.C., Carey V.J., Bates D.M., Bolstad B., Dettling M., Dudoit S., Ellis B., Gautier L., Ge Y., Gentry J., Hornik K., Hothorn T., Huber W., Iacus S., Irizarry R., Leisch F., Li C., Maechler M., Rossini A.J., Sawitzki G., Smith C., Smyth G., Tierney L., Yang J.Y., Zhang J. Bioconductor: open software development for computational biology and bioinformatics. Genome Biology 2004, 5:R80.
18. Giskeodegard G.F., Grinde M.T., Sitter B., Axelson D.E., Lundgren S., Fjosne H.E., Dahl S., Gribbestad I.S., Bathen T.F. Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. Journal of Proteome Research 2010, 9:972-979.
19. Glunde K., Jie C., Bhujwalla Z.M. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Research 2004, 64:4270-4276.
20. Jagannathan N.R., Kumar M., Seenu V., Coshic O., Dwivedi S.N., Julka P.K., Srivastava A., Rath G.K. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. British Journal of Cancer 2001, 84:1016-1022.
21. Jubb A.M., Miller K.D., Rugo H.S., Harris A.L., Chen D., Reimann J.D., Cobleigh M.A., Schmidt M., Langmuir V.K., Hillan K.J., Chen D.S., Koeppen H. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clinical Cancer Research 2011, 17:372-381.
22. Katz-Brull R., Seger D., Rivenson-Segal D., Rushkin E., Degani H. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Research 2002, 62:1966-1970.
23. Kerbel R.S. Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. Breast 2009, 18(Suppl 3):S41-S47.
24. Lindholm E.M., Kristian A., Nalwoga H., Kruger K., Nygard S., Akslen L.A., Maelandsmo G.M., Engebraaten O. Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts. Molecular Oncology 2012, 6:418-427.
25. Mannelqvist M., Stefansson I.M., Bredholt G., Hellem B.T., Oyan A.M., Jonassen I., Kalland K.H., Salvesen H.B., Akslen L.A. Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer. American Journal of Pathology 2011, 178:861-871.
26. Meisamy S., Bolan P.J., Baker E.H., Bliss R.L., Gulbahce E., Everson L.I., Nelson M.T., Emory T.H., Tuttle T.M., Yee D., Garwood M. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy-a pilot study at 4 T. Radiology 2004, 233:424-431.
27. Milosevic J., Maisel M., Wegner F., Leuchtenberger J., Wenger R.H., Gerlach M., Storch A., Schwarz J. Lack of hypoxia-inducible factor-1 alpha impairs midbrain neural precursor cells involving vascular endothelial growth factor signaling. Journal of Neuroscience 2007, 27:412-421.
28. Moestue S.A., Borgan E., Huuse E., Lindholm E., Sitter B., Børresen-Dale A.L., Engebråten O., Maelandsmo G., Gribbestad I.S. Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer 2010, 10:433.
29. Morse D.L., Raghunand N., Sadarangani P., Murthi S., Job C., Day S., Howison C., Gillies R.J. Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P NMR spectroscopy of cell extracts. Magnetic Resonance in Medicine 2007, 58:270-280.
30. Nishikawa K.C., Millis A.J. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Experimental Cell Research 2003, 287:79-87.
31. Oganesian A., Armstrong L.C., Migliorini M.M., Strickland D.K., Bornstein P. Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells. Molecular Biology of the Cell 2008, 19:563-571.
32. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
33. Podo F., Canevari S., Canese R., Pisanu M.E., Ricci A., Iorio E. MR evaluation of response to targeted treatment in cancer cells. NMR in Biomedicine 2011, 24:648-672.
34. Rubenstein J.L., Kim J., Ozawa T., Zhang M., Westphal M., Deen D.F., Shuman M.A. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000, 2:306-314.
35. Saidi A., Javerzat S., Bellahcene A., De V.J., Bello L., Castronovo V., Deprez M., Loiseau H., Bikfalvi A., Hagedorn M. Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. International Journal of Cancer 2008, 122:2187-2198.
36. Schneider B.P., Sledge G.W. Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners?. Journal of Clinical Oncology 2011, 29:2444-2447.
37. Schneider B.P., Wang M., Radovich M., Sledge G.W., Badve S., Thor A., Flockhart D.A., Hancock B., Davidson N., Gralow J., Dickler M., Perez E.A., Cobleigh M., Shenkier T., Edgerton S., Miller K.D. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. Journal of Clinical Oncology 2008, 26:4672-4678.
38. Sitter B., Sonnewald U., Spraul M., Fjosne H.E., Gribbestad I.S. High-resolution magic angle spinning MRS of breast cancer tissue. NMR in Biomedicine 2002, 15:327-337.
39. Smith I., Pierga J.Y., Biganzoli L., Cortes-Funes H., Thomssen C., Saracchini S., Nisenbaum B., Pelaez I., Duenne A.A., Pritchard K.I. Final overall survival results and effect of prolonged (>/=1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. Breast Cancer Research Treatment 2011, 130:133-143.
40. Smyth G.K. Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions Using R and Bioconductor 2011, 397-420. Springer, New York. R. Gentleman, V. Carey, S. Dudoit, R. Irizarry, W. Huber (Eds.).
41. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Statistical Application in Genetics and Molecular Biology 2004, 3. Article3.
42. Smyth G.K., Michaud J., Scott H.S. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 2005, 21:2067-2075.
43. Sotiriou C., Wirapati P., Loi S., Harris A., Fox S., Smeds J., Nordgren H., Farmer P., Praz V., Haibe-Kains B., Desmedt C., Larsimont D., Cardoso F., Peterse H., Nuyten D., Buyse M., Van d.V., Bergh J., Piccart M., Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. Journal of the National Cancer Institute 2006, 98:262-272.
44. Troyanskaya O., Cantor M., Sherlock G., Brown P., Hastie T., Tibshirani R., Botstein D., Altman R.B. Missing value estimation methods for DNA microarrays. Bioinformatics 2001, 17:520-525.
45. Vargo-Gogola T., Rosen J.M. Modelling breast cancer: one size does not fit all. National Reviews Cancer 2007, 7:659-672.
46. Von Minckwitz G., Eidtmann H., Rezai M., Fasching P.A., Tesch H., Eggemann H., Schrader I., Kittel K., Hanusch C., Kreienberg R., Solbach C., Gerber B., Jackisch C., Kunz G., Blohmer J.U., Huober J., Hauschild M., Fehm T., Muller B.M., Denkert C., Loibl S., Nekljudova V., Untch M. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. The New England Journal of Medicine 2012, 366:299-309.
47. Yang S.X., Steinberg S.M., Nguyen D., Wu T.D., Modrusan Z., Swain S.M. Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clinical Cancer Research 2008, 14:5893-5899.
48. Young S.D., Hill R.P. Effects of reoxygenation on cells from hypoxic regions of solid tumors: anticancer drug sensitivity and metastatic potential. Journal of the National Cancer Institute 1990, 82:371-380.